Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of PEG-G-CSF injection for prevention of chemotherapy-induced neutropenia in breast cancer
CTR20244457Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegfilgrastim in neutropenia, febrile neutropenia (FN), sponsored by Sinovac Biotech Ltd.. Started Dec 2024; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on CTR20244457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244457.